The therapeutic potential of glucagon-like peptide-1 receptor agonists (GLP1RAs), such as semaglutide, and dual GIP receptor (GIPR)/GLP1RAs, like tirzepatide, extends beyond metabolic diseases like diabetes and obesity [1, 2]. Here, GIPR is linked to metabolic disease.